Literature DB >> 11352765

Cell cycle-dependent effects of wortmannin on radiation survival and mutation.

S B Chernikova1, K L Lindquist, M M Elkind.   

Abstract

Wortmannin, a known radiation sensitizer, has been used in experiments with synchronized cells to compare its effect on radiation survival and mutation induction within the cell cycle. PL61 cells (CHO cells with an inactivated HPRT gene containing a single active copy of a bacterial gpt gene) were synchronized by mitotic selection. Wortmannin administered before gamma irradiation caused a greater sensitization in G(1)-phase cells relative to late S/G(2)-phase cells. Preferential radiosensitization of G(1)-phase cells by wortmannin sets a limit to the proposed use of wortmannin in radiation therapy, since, in contrast to normal tissues, tumors usually have high proportions of S-phase cells. Wortmannin increased mutation frequencies in both G(1)- and S/G(2)-phase cells. Interestingly, relative increases in radiation-induced mutations in G(1) and S/G(2) phases were comparable. The results are discussed in terms of the contributions of different repair modes in the production of mutations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352765     DOI: 10.1667/0033-7587(2001)155[0826:ccdeow]2.0.co;2

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  3 in total

1.  Cell cycle dependence of ionizing radiation-induced DNA deletions and antioxidant radioprotection in Saccharomyces cerevisiae.

Authors:  Kurt Hafer; Leena Rivina; Robert H Schiestl
Journal:  Radiat Res       Date:  2010-06       Impact factor: 2.841

2.  Vanillins--a novel family of DNA-PK inhibitors.

Authors:  Stephen Durant; Peter Karran
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

3.  Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.

Authors:  Sophia B Chernikova; Rochelle B Nguyen; Jessica T Truong; Stephano S Mello; Jason H Stafford; Michael P Hay; Andrew Olson; David E Solow-Cordero; Douglas J Wood; Solomon Henry; Rie von Eyben; Lei Deng; Melanie Hayden Gephart; Asaithamby Aroumougame; Claudia Wiese; John C Game; Balázs Győrffy; J Martin Brown
Journal:  J Clin Invest       Date:  2018-10-29       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.